Drug-impregnated encasement
Abstract
[Task]An improved drug impregnated sleeve provides the offer. A drug impregnated sleeve for encapsulating a medical implant is provided... ThisSleeveIsIncludes a body made of biologically compatible material, defining an internal cavity configured to receive medical implants.. ThisA biologically compatible material is bioreabsorptive. The body can include multiple openings such as perforations, holes, etc. that extend from the cavity through the body. The sleeve can further include a first end, a second end, and a drug impregnated in a reabsorbable sheet... SoThe first end of the sleeve may be open and the second end may be closed to receive the medical implant through it. The implant can be encapsulated in a sleeve and implanted in the patient, and over time, the drug is administered in vivo from there to the tissue surrounding the implantation site.[Selection diagram]None.

Term
Projected expiry 24 September 2032.
- Priority
- Filed
- Published
- Today
- Projected expiry
25 claims: 2 independent, 23 dependent
- 1生物学的に適合性のあるインプラントであって、以下:細長いプレート;および スリーブを備え:該スリーブが、 生物学的に適合性のある再吸収性の材料から作製され、かつ該細長いプレートの形状と相補的である形状を有する内部空洞を規定する本体であって、該本体を貫通して該空洞から延びる複数の開口部を規定し、該複数の開口部が該本体の全表面積の10%~20%である合わせた開いた面積を有する、本体と、 該細長いプレートを受容するように構成された第1の端部と、 該細長いプレートを保持するために閉じている第2の端部と、 該材料に含浸させた薬物とを備える、生物学的に適合性のあるインプラント。
- 2請求項1に記載のインプラントであって、前記スリーブが前記細長いプレートの第1の端部分を受容するよう構成される第1のスリーブであり、該インプラントが、以下:生物学的に適合性のある再吸収性の材料から作製され、かつ該細長いプレートの形状と相補的である形状を有する内部空洞を規定する本体であって、該本体を貫通して該空洞から延びる複数の開口部を規定し、該複数の開口部が該本体の全表面積の10%~20%である合わせた開いた面積を有する、本体と、 該細長いプレートの第2の端部を受容するように構成された第1の端部と、 該細長いプレートを保持するために閉じている第2の端部と、 該材料に含浸させた薬物とを備える、第2のスリーブをさらに備える、生物学的に適合性のあるインプラント。
- 3前記再吸収性の材料が、2つ以上の層を備える、請求項1または2のいずれかに記載のインプラント。
- 4前記2つ以上の層の少なくとも1つが、細孔質である、請求項3に記載のインプラント。
- 5前記2つ以上の層の少なくとも2つの層が、異なる薬物を含む、請求項3に記載のインプラント。
- 6前記2つ以上の層の少なくとも2つの層が、同じ薬物を含む、請求項3に記載のインプラント。
- 7前記2つ以上の層の少なくとも2つの層が、インビボで異なる速度で分解するよう構成されている、請求項3に記載のインプラント。
- 8前記スリーブが、継目に沿って一緒に保持されるシートを含む、請求項1または2のいずれかに記載のインプラント。
- 9前記継目が、前記第2の端部を閉じる、請求項8に記載のインプラント。
- 10前記シートが、前記薬物を該シートの1つの側面のみから放出されるよう構成される、請求項8に記載のインプラント。
- 11前記シートが、0.04mmから0.1mmの厚さを有する、請求項8に記載のインプラント。
- 12前記スリーブが、上面および下面を有し、該上面または下面の少なくとも一部分が実質的に平面である、請求項1または2のいずれかに記載のインプラント。
- 13前記薬物が、抗生物質、防腐薬、鎮痛薬、抗腫瘍薬、ビスホスホネート、成長因子、ペプチド、スタチンおよびこれらの組合せからなる群から選択される、請求項1または2のいずれかに記載のインプラント。
- 14前記開口部が、丸い穿孔である、請求項1または2のいずれかに記載のインプラント。
- 15前記開口部が、丸穴、楕円穴、スリット、スロットおよびこれらの任意の組合せからなる群から選択される形態を有する、請求項1または2のいずれかに記載のインプラント。
- 16前記複数の開口部の各々が、少なくとも1.5mmの直径を有する、請求項1または2のいずれかに記載のインプラント。
- 17前記複数の開口部が、前記シートの全表面積の20%である合わせた開いた面積を有する、請求項1または2のいずれかに記載のインプラント。
- 18前記スリーブが、前記薬物を2つ以上の異なる速度で放出するよう構成されている、請求項1または2のいずれかに記載のインプラント。
- 19前記再吸収性の材料が、0.02mm~0.5mmの厚みを有する、請求項1または2のいずれかに記載のインプラント。
- 20前記スリーブが、初期非伸張寸法の100%まで破壊されることなく伸張し得る、請求項1または2のいずれかに記載のインプラント。
- 21前記再吸収性の材料が、ポリカプロラクトンを含む、請求項1または2のいずれかに記載のインプラント。
- 22前記再吸収性の材料が、30%のポリカプロラクトンおよび70%のポリ乳酸を含む、請求項1または2のいずれかに記載のインプラント。
- 23移植可能なスリーブを形成する方法であって、 少なくとも1つの薬物が含浸された、生物学的に適合性のある材料の全体に平らな少なくとも1つの第1のシートを提供する工程、 該シートに複数の開口部を形成する工程であって、該複数の開口部が該シートの全表面積の10%~20%である合わせた開いた面積を有する、工程、 丸められた縁と、反対側の自由縁と、第1の開いた端部と、該第1の端部の反対側の第2の開いた端部とを形成するために、該シートを折り畳む工程、 該自由縁を閉じるために該自由縁に沿って継目を形成する工程、および 該第2の端部を閉じるために該第2の端部に沿って継目を形成する工程を包含し、 折り畳まれ、かつ形成されたシートが細長いプレートの形状と相補的である形状を有する内部空洞を規定する、方法。
- 24前記継目が、熱融合、化学融合および接着からなる群から選択される方法によって形成される、請求項23に記載の方法。
- 25前記複数の開口部を形成する前に、少なくとも1つの薬物を含浸させた生物学的に再吸収性の材料の全体に平らな第2のシートを、前記第1のシート上に積層する工程をさらに包含する、請求項23に記載の方法。
Independent claims25
34 paragraphs, as filed
(Field of invention) The present invention relates to a modified drug-impregnated encasement configured and adapted to receive a medical implant, more specifically, in one embodiment, shaping various types, sizes and shapes. With respect to a sleeve for delivering the drug to the implantation site, which serves to contain the surgical implant.
(Background of invention) Bacterial colonization on the implant surface often results in infection. Systemic antibiotics can reduce the risk of infection, but even in the presence of systemic prophylactic antibiotics, infection still occurs on the surface of the implant. Treating the implantation site with topical antibiotics or other bioactive agents is not uncommon for orthopedic surgeons. In some cases, the surgeon mixes the antibiotic with PMMA bone cement to provide a storage area for the topical antibiotic. In other cases, bioresorbable surface coatings or films have been developed that can be applied to orthopedic implants to provide a more uniform and convenient solution. The coating can be impregnated with a drug or an antibiotic such as gentamicin. Such coatings can be applied to various orthopedic implants such as tibial nails or other nails, plates, screws. Generally, such coatings are obtained from reabsorptive polymers, so when the drug is depleted, the implant remains and the coating dissolves.
One problem with coated implants is that each of these coated implants is a new development product and its coating method, new packaging and sterilization methods must be validated. In addition, each coated implant is subject to a separate regulatory application. As a result, a large amount of paperwork for drug-coated implants can be a daunting task. This logistical problem is exacerbated by the prospect of using a variety of coatings containing materials such as analgesics, antitumor agents, bisphosphonates, growth promoters and the like.
Given the potential number, size and shape of coated products, the regulatory, financial and logistical burden of providing uncoated and coated implants is enormous. This problem is exacerbated when considering the use of additional drugs such as analgesics, antitumor agents, growth promoters, etc. in this coating. Moreover, in some of these cases, the drug must be delivered into the bone rather than the surrounding soft tissue, which can form most of the tissue contact zone of a typical implant.
<p> (Gist of the invention) Therefore, there is still a need for improved drug release means that can be adapted to a wide variety of implants in general and provide a cost-effective solution to the limitations of conventional surface coatings.</p>
<p> The present invention generally targets improved drug impregnated containers. The container is preferably made from a biologically compatible material. As used herein, a biologically compatible material is broadly defined as any FDA-approved material suitable for implantation in a patient. In a preferred embodiment, the container is made from a bioreabsorptive material. However, it is not limited to this. In a preferred embodiment, the container is configured as a sleeve. The present invention provides a "one-size fits all" solution to the above problems of coated implants. Instead of stocking a large number of different coated implants, an alternative is provided with a drug impregnated sleeve that is preferably compatible with a range of conventional uncoated different implants. Therefore, according to one aspect of the invention, one size fits all.</p><p> According to another aspect of the invention, the sleeve is implanted in the patient and over time the drug is administered from the sleeve to the tissue surrounding the implantation site in vivo. In one embodiment, the selection of sleeve material used, the structure of the sleeve, the type and form of the drug or combination of drugs, and / or the drug delivery system impregnating the sleeve, etc., as further described herein. The factor regulates the duration and dose of the drug delivered from the sleeve to the patient.</p><p> According to another aspect of the invention, the surgeon can advantageously modify and adapt the drug impregnated sleeve to individually adapt the sleeve to the particular size and shape of the implant that needs to be encapsulated. Even more advantageously, in one embodiment, the surgeon can change the sleeve in the operating room and then slide it over the implant. This method is uncertain to the surgeon what type or size of implant, eg bone plate, is needed for the bone fixation procedure until the implant site is accessible for visual observation and measurement during surgery. It is useful in such cases. This allows the surgeon to choose the right type and size of implant and cut the drug impregnated sleeve to fit.</p><p> One or several exemplary drugs or bioactive agents that can be impregnated in the sleeve are, but are not limited to, antibiotics, preservatives, analgesics, antitumor agents, bisphosphonates, growth factors, peptides, statins. Etc. are included. It should be understood that any type of drug or bioactive agent can be incorporated into the sleeve and that the invention is not limited by the type used. It should be noted that the term "drug" herein is broadly defined as any medically relevant bioactive substance that can be beneficially incorporated into the sleeve for administration to the implantation site of a medical implant. I want to. It should also be noted that the present invention can be used with any type of medical implant (defined herein as including dental implants) and is not expressly limited to use with orthopedic implants only. I want to be.</p><p> A preferred embodiment of a drug-impregnated sleeve that encloses a medical implant is generally a body made of at least one sheet of biocompatible material, a first end, and a second end. And the drug impregnated in the sheet. In one embodiment, the biologically compatible material is bioreabsorptive. In one embodiment, the drug is administered in vivo from the sleeve to the patient's implantation site after the medical implant has been attached. In one embodiment, the body defines an internal cavity configured to receive a medical implant. In one embodiment, preferably, the body further comprises a plurality of openings extending through the body from this cavity. In one embodiment, their openings are round perforations. In another embodiment, those openings may have a form selected from the group consisting of round holes, elliptical holes, slits, slots and any combination thereof. In one embodiment, the medical device may be an orthopedic device, and in some embodiments, the orthopedic device may be a bone fixation plate or an intramedullary nail such as a tibial nail, a femoral nail, etc. .. Preferably, the first end of the sleeve may be open and the second end may be closed to receive the medical implant through it. In one embodiment, the sleeve has an elongated shape throughout. In another embodiment, the sleeve has an upper surface and a lower surface, and at least a portion of the upper surface or the lower surface is substantially flat. In another embodiment, the sleeve comprises a first edge, the first edge having a seam closing the first edge, and a second end including a seam closing the second end.</p><p> In one embodiment, preferably the reabsorptive sheet contains a polymer, more preferably adding flexibility and suppleness to the sleeve and sliding the sleeve over the implant into the overall shape of the implant. The reabsorbable sheet contains caprolactone to facilitate the sleeve obedience. In one embodiment, the sheet may contain different salts of the same drug to regulate the rate and duration of release of the drug to the patient. In another embodiment, the sheet comprises two different drugs. In another embodiment, the sleeve is made from at least two reabsorbable material sheets laminated together. In some embodiments, at least one sheet may be microporous. In another embodiment, at least two sheets may contain different drugs.</p><p> Another possible embodiment of a drug-impregnated sleeve that encloses a medical implant is generally at least one sheet made of a biologically compatible material and at least one drug impregnated into the sheet. Including. In one embodiment, this biologically compatible material is bioreabsorptive. The sheet can include multiple openings, and in one embodiment those openings may be round perforations or holes. In one embodiment, the sheet is folded to create a rounded edge, a free edge on the opposite side, a first end, and a second end on the opposite side of the first end. In one embodiment, a seam is formed along the free edge and the second end so as to close the free edge and the second end. In one embodiment, the first end defines an opening configured to receive a medical implant through it so that it is at least partially encapsulated by the sleeve. The sleeve can be sized and configured to follow the general shape of the type and size of the medical implant intended to be contained within the sleeve.</p><p> Also provided is a method of forming a drug impregnated sleeve. This method provides at least one first sheet that is flat throughout the biologically compatible material impregnated with at least one drug, forming multiple openings in this sheet. Fold the sheet to form a rounded edge, a free edge on the opposite side, a first open end, and a second open end on the opposite side of the first end. This includes forming a seam along the free edge to close the free edge, and forming a seam along the second end to close the second end. The seam forming step for the free edge and the seam forming step for the second end can be performed in any order. In another embodiment, the method further forms multiple openings and a second flat throughout the biologically reabsible material impregnated with at least one drug before folding the sheet. Includes the step of laminating the sheets onto the first sheet. In one embodiment, the biologically compatible material is bioreabsorptive.</p><p> The above features and advantages of the present invention as well as other features and advantages will become apparent from the rest of the disclosure, particularly the following detailed description of preferred embodiments. All of these preferred embodiments illustrate the principles of the invention.<u style="single"> For example, the invention of the present application provides the following.</u><u style="single">(Item 1)</u><u style="single"> A body made of a biologically compatible material that defines an internal cavity configured to receive a medical implant, with a body containing multiple openings that penetrate and extend from the cavity. ,</u><u style="single"> The first end and</u><u style="single"> The second end and</u><u style="single"> With the drug impregnated in the above material</u><u style="single"> Biologically compatible sleeves, including.</u><u style="single">(Item 2)</u><u style="single"> The sleeve according to item 1, wherein the biologically compatible material is bioreabsorptive.</u><u style="single">(Item 3)</u><u style="single"> The sleeve of item 2, wherein the first end is open to receive the medical implant through the first end and the second end is closed.</u><u style="single">(Item 4)</u><u style="single"> Item 2. The sleeve having an elongated shape.</u><u style="single">(Item 5)</u><u style="single"> The sleeve according to item 2, which has an upper surface and a lower surface, and at least a part of the upper surface or the lower surface is substantially flat.</u><u style="single">(Item 6)</u><u style="single"> Item 2. The sleeve according to item 2, made from at least one sheet of biocompatible material.</u><u style="single">(Item 7)</u><u style="single"> 6. The sleeve of item 6, wherein the sleeve comprises a first edge, the first edge having a seam closing the first edge, and the second end including a seam closing the second end. ..</u><u style="single">(Item 8)</u><u style="single"> Item 7. The sleeve according to item 7, wherein the seam is formed by a method selected from the group consisting of thermal fusion, chemical fusion and adhesion.</u><u style="single">(Item 9)</u><u style="single"> The sleeve according to item 2, wherein the reabsorbable sheet contains a polymer.</u><u style="single">(Item 10)</u><u style="single"> The sleeve according to item 2, wherein the reabsorptive sheet contains caprolactone.</u><u style="single">(Item 11)</u><u style="single"> Item 2. The sleeve according to item 2, wherein the reabsorbent sheet is made of 30% polycaprolactone and 70% polylactic acid.</u><u style="single">(Item 12)</u><u style="single"> Item 2. The sleeve according to item 2, which is configured to receive a portion of a medical implant and contains a fitted pocket at each end.</u><u style="single">(Item 13)</u><u style="single"> The sleeve according to item 2, which has an open central portion.</u><u style="single">(Item 14)</u><u style="single"> Item 2. The sleeve according to item 2, wherein the drug is selected from the group consisting of antibiotics, antiseptic agents, analgesics, antitumor agents, bisphosphonates, growth factors, peptides, statins and combinations thereof.</u><u style="single">(Item 15)</u><u style="single"> The sleeve according to item 2, wherein the opening is a round perforation.</u><u style="single">(Item 16)</u><u style="single"> The sleeve of item 2, wherein the opening has a form selected from the group consisting of round holes, elliptical holes, slits, slots and any combination thereof.</u><u style="single">(Item 17)</u><u style="single"> Item 2. The sleeve according to item 2, made from at least two reabsorbable material sheets laminated together.</u><u style="single">(Item 18)</u><u style="single"> The sleeve according to item 17, wherein at least one sheet is microporous.</u><u style="single">(Item 19)</u><u style="single"> The sleeve according to item 17, wherein at least two of the above sheets contain different drugs.</u><u style="single">(Item 20)</u><u style="single"> The sleeve according to item 17, wherein at least two of the above sheets contain the same drug.</u><u style="single">(Item 21)</u><u style="single"> The sleeve according to item 2, wherein the sheet contains different salts of the same drug.</u><u style="single">(Item 22)</u><u style="single"> The sleeve according to item 2, wherein the sheet contains two different drugs.</u><u style="single">(Item 23)</u><u style="single"> The sleeve according to item 2, wherein the drug is administered in vivo from the sleeve to the implantation site of a medical implant in the patient's body.</u><u style="single">(Item 24)</u><u style="single"> At least one sheet made of a biologically compatible material, containing at least one drug impregnated into the sheet, the sheet containing multiple openings, with rounded edges and. A sheet folded to create a free edge on the opposite side, a first end, and a second end on the opposite side of the first end.</u><u style="single"> A seam formed along the free edge and the second end, and a seam that closes the free edge and the second end.</u><u style="single"> Including</u><u style="single"> The first end defined an opening configured to receive a medical implant so that it was at least partially contained by the sleeve.</u><u style="single"> Drug impregnated sleeve.</u><u style="single">(Item 25)</u><u style="single"> The sleeve according to item 24, wherein the sheet material is bioreabsorptive.</u><u style="single">(Item 26)</u><u style="single"> 24. The sleeve of item 24, wherein the opening is a round perforation.</u><u style="single">(Item 27)</u><u style="single"> 24. The sleeve of item 24, wherein the opening has a form selected from the group consisting of round holes, elliptical holes, slits, slots and any combination thereof.</u><u style="single">(Item 28)</u><u style="single"> 24. The sleeve according to item 24, which has an elongated shape.</u><u style="single">(Item 29)</u><u style="single"> 24. The sleeve of item 24, which has an upper surface and a lower surface, wherein at least a portion of the upper surface or the lower surface is substantially flat.</u><u style="single">(Item 30)</u><u style="single"> 24. The sleeve of item 24, wherein the seams are formed by a method selected from the group consisting of thermal fusion, chemical fusion and adhesion.</u><u style="single">(Item 31)</u><u style="single"> 24. The sleeve of item 24, wherein the reabsorptive sheet contains caprolactone.</u><u style="single">(Item 32)</u><u style="single"> 24. The sleeve according to item 24, which comprises a polymer.</u><u style="single">(Item 33)</u><u style="single"> Item 24. The sleeve of item 24, made from at least two reabsorbable material sheets laminated together.</u><u style="single">(Item 34)</u><u style="single"> 33. The sleeve according to item 33, wherein at least one sheet is microporous.</u><u style="single">(Item 35)</u><u style="single"> A method of forming a drug impregnated sleeve</u><u style="single"> To provide at least one flat first sheet across a biologically compatible material impregnated with at least one drug,</u><u style="single"> Forming multiple openings in the sheet,</u><u style="single"> Fold the sheet to form a rounded edge, a free edge on the opposite side, a first open end, and a second open end on the opposite side of the first end. thing,</u><u style="single"> Forming a seam along the free edge to close the free edge, and</u><u style="single"> Forming a seam along the second end to close the second end</u><u style="single"> Including</u><u style="single"> The seam forming step for the free edge and the seam forming step for the second end can be performed in any order.</u><u style="single"> Method.</u><u style="single">(Item 36)</u><u style="single"> 35. The sleeve according to item 35, wherein the opening is a round perforation.</u><u style="single">(Item 37)</u><u style="single"> 35. The sleeve of item 35, wherein the opening has a form selected from the group consisting of round holes, elliptical holes, slits, slots and any combination thereof.</u><u style="single">(Item 38)</u><u style="single"> 35. The sleeve according to item 35, wherein the sleeve has an elongated shape.</u><u style="single">(Item 39)</u><u style="single"> 35. The sleeve of item 35, wherein the sleeve has an upper surface and a lower surface, and at least a portion of the upper surface or the lower surface is substantially flat.</u><u style="single">(Item 40)</u><u style="single"> 35. The sleeve of item 35, wherein the seams are formed by a method selected from the group consisting of thermal fusion, chemical fusion and adhesion.</u><u style="single">(Item 41)</u><u style="single"> 35. The sleeve according to item 35, wherein the reabsorptive sheet contains caprolactone.</u><u style="single">(Item 42)</u><u style="single"> 35. The sleeve of item 35, wherein the reabsorptive sheet is formed from at least one polymer.</u><u style="single">(Item 43)</u><u style="single"> Prior to forming the plurality of openings, a step of laminating a second sheet, which is flat throughout the biologically reabsible material impregnated with at least one drug, onto the first sheet. The sleeve according to item 35, further including.</u><u style="single">(Item 44)</u><u style="single"> 35. The sleeve according to item 35, wherein the biologically compatible material is bioreabsorptive.</u></p>
Next, the features of the preferred embodiment will be described with reference to the following drawings. In these drawings, similar elements are similarly labeled.<figref num="1">FIG. 1 is a top view of an embodiment of a drug impregnated sleeve based on the principles of the present invention and a medical implant in the form of a bone plate that can be inserted into the sleeve.</figref><figref num="2">FIG. 2 is a side sectional view of the sleeve of FIG.</figref><figref num="3">FIG. 3 is a side sectional view of an alternative embodiment of the sleeve of FIG. 1 comprising a plurality of sheet or film layers.</figref><figref num="4">FIG. 4 is a top view of the sleeve of FIG. 1 in which the bone plate is partially inserted into the sleeve.</figref><figref num="5">FIG. 5 is a side view of an alternative embodiment of a drug impregnated sleeve having open-ended pockets formed at both ends of the sleeve.</figref><figref num="6">FIG. 6 is a top view of an alternative embodiment of a drug impregnated sleeve having a deformable opening in the form of a slot.</figref><figref num="7">FIG. 7 is a top view of an alternative embodiment of a drug impregnated sleeve having a deformable opening in the form of a slit.</figref><figref num="8">FIG. 8 is a top view of an alternative embodiment of a drug impregnated sleeve having a deformable opening in the form of slits and holes.</figref><figref num="9">FIG. 9 is a top view of an alternative embodiment of a drug impregnated sleeve having a deformable opening in the form of an x-shaped slit.</figref><figref num="10">FIG. 10 is a perspective view of a tubular alternative drug impregnated sleeve.</figref>
(Detailed description of preferred embodiments) Next, preferred embodiments shown for illustration purposes only will be described with reference to the accompanying drawings so that the present invention will be understood. Therefore, those preferred embodiments are described for convenience of reference, and the invention is not limited to the embodiments described herein. The scope of the present invention is defined by the scope of claims attached herein.
FIG. 1 shows a drug impregnated sleeve 10 based on the principles of the invention placed next to a medical device such as an orthopedic implant 30, and in one non-limiting embodiment shown, the medical device is elongated. It is a bone plate. FIG. 2 shows a cross-sectional view of the sleeve 10 of FIG.
With reference to FIGS. 1 and 2, a preferred embodiment of the drug impregnated sleeve 10 comprises an elongated body 20 having two ends 21, 22. The ends 21 and 22 may be open or closed. In one embodiment, preferably the end 21 is an open end through which the implant can be inserted into the sleeve 10. In one embodiment, the contralateral end 22 is preferably the closed end so that the implant fits snugly against this closed end to achieve a better fit and to the patient's surgical site. It is possible to prevent the sleeve from sliding against the implant when the implant is fixed.
In one embodiment, the sleeve 10 can be formed from a single thin sheet or film 12 of biologically compatible material. In a preferred embodiment, the biocompatible material is bioreabsorptive. Prior to forming the sleeve 10, the sheet 12 is preferably flat throughout. In a preferred embodiment, the sheet 12 may be made of a biodegradable reabsorptive polymer, which dissolves over time when implanted in vivo, is absorbed by the patient and the implant is reabsorbed. If it is not made of sex material, leave only the implant later. Alternatively, in another embodiment, the implant is also made of a reabsorbent material, in which case both the implant and the sleeve will eventually dissolve. In one preferred embodiment, the sheet 12 may be generally thin and substantially flat, with the sheet 12 being, but not limited to, about 0.02 mm to 0.5 mm, more preferably about 0.04 mm to 0.1 mm. It can have a range of general and exemplary thickness T. However, any suitable sheet thickness T can be used, depending on the intended use, consideration for tear resistance when inserting the implant into the sheet, duration of drug administration, and the like. The sheet 12 can be made by any suitable means known in the art.
In another embodiment, the drug delivery sleeve 10 can be formed by a weaving process such as braiding, knitting, weaving. In one embodiment, the woven sleeve can be manufactured using fibers impregnated therein with the drug of interest. In one embodiment, the fabric may be formed from drug-free bioreabsorptive fibers impregnated therein. In that case, the textile material is then coated with a layer of elastic bioreabsorptive polymer containing the drug of interest. In one embodiment, a woven implant in the form of a strip, such as an elastic material, woven cloth, etc., in which one or more surfaces are coated with a bioresorbable adhesive so that it can be adhered to the implant is also manufactured. obtain. In one embodiment, the textile material and / or adhesive component may include the drug of interest.
In one embodiment of the flexible sleeve, the reabsorptive polymer used in the sheet 12 preferably comprises a polycouplercton. Polymers, including at least some flexible reabsorptive polymers (eg caprolactone), advantageously have good flexibility and good strength properties. In one embodiment, a flexible sleeve (eg made from polycouplercton) can easily stretch to follow the size and shape of the implant, but resist tearing while stretching the sleeve over the implant. Has sufficient strength to do. In a preferred embodiment, preferably the sheet 12 containing caprolactone can be stretched up to about 100% of its unstretched initial length or width. Advantageously, a single extensible sleeve can accommodate a wide range of implant sizes and / or shapes, preferably in one preferred embodiment, with only a few surgeons as described herein. It fits relatively snugly on top of a medical implant with or without any changes. In one embodiment, the invention includes a kit comprising a limited number of sleeves of different sizes and / or shapes that can fit into most of the implant product line.
In one embodiment of the flexible reabsorptive sleeve 10 with sufficient flexibility, the sheet 12 may consist of polycaprolactone and another reabsorptive polymer. An exemplary and non-limiting preferred range of polycaprolactone content for the sleeve is from about 10% to about 100%, more preferably from about 20% to 30%. In contrast to some other reabsible polymers commonly used for implantation, polycaprolactone decomposes relatively slowly in vivo. Therefore, caprolactone has a shorter in vivo degradation time to regulate the overall degradation rate of the sheet 12, while still maintaining sufficient flexibility to stretch the sleeve 10 on the medical implant. Can be mixed with other polymers. In one possible embodiment, the sheet 12 may be made of 30% polycaprolactone and 70% polylactic acid.
It should be understood that with sleeve 10, any other suitable percentage of polylaclastone can be used. It should also be appreciated that other reabsorptive polymers or combinations of polymers can be used with or without polycaprolactone to make Sheet 12. For example, the polymer can consist of various combinations of any FDA-approved monomer, including glycolide, lactide, trimethylenecarbonate, dioxanone and caprolactone. The film or fiber can further include synthetic polymers such as polyethylene oxide, bioreabsorptive polyurethane. In another embodiment, the film or fiber used to form the drug impregnated sleeve can also include natural biopolymers such as gelatin, collagen, chitosan, hyaluronate, alginate. Thus, the invention is not limited to the type of material used to make the sheet 12, the type of polymer, or the type of combination of polymer or other types of material.
In one preferred embodiment, preferably the sleeve 10 further allows the passage or transport of fluid through the sleeve in one possible embodiment, a plurality of openings or perforations 14 (substantially) of any suitable shape. Includes a round perforation or opening 14). The perforation 14 does not have to be perfectly round and may have an oval or oval shape in some embodiments (not shown). The opening 14 is not limited to the round perforation 14. The perforation 14 preferably extends from the inner surface 11 to the outer surface 13 through the sheet 12 (see FIG. 2). Advantageously, when the drug or bioactive agent leaches out of the polymer, the perforations 14 distribute the drug or bioactive agent more evenly to adjacent tissues and bones than a sleeve without such perforations. To do. In addition to favoring drug distribution, the perforation 14 also eliminates the dead space between the implant and the sleeve where debris or material is trapped and remains there, which can cause problems for the patient. To do. Therefore, the flow of bodily fluids allows such debris to be flushed through the perforations 14.
An exemplary and non-limiting preferred range of porosity based on the percentage of open area provided by the perforations 14 to the total surface area of the sheet 12 is from about 10% to about 80%, more preferably from about 20%. It is about 50%. In one preferred embodiment, the perforation 14 provides a porosity of about 20%. For satisfactory drug distribution and flushing, the perforation 14 preferably has a diameter of at least about 0.1 mm. In a preferred embodiment, the perforation 14 has a diameter of at least about 1.5 mm. In the art, diameters of about 0.1 mm and above are generally considered to represent macropores.
Preferably, in one embodiment, the perforations 14 are drilled while the sheet 12 is in a generally flat state prior to being formed on the sleeve 10, as further described herein.
In one embodiment, the sleeve 10 can be made using a sheet of degradable polymer that has been heat treated and compression molded. In one embodiment, the polymer may dissolve or disperse a drug or other bioactive substance in the polymer while it is still in the form of a solution. In one embodiment, the polymer solution is then processed into a sheet or film using conventional methods known in the art, perforated, and then as a sleeve as described herein. It is molded. Preferably, the sheet 12 can be perforated by any suitable technique, for example by using a press in one embodiment, while the sheet 12 is still flat throughout.
In one embodiment, the sheet was perforated by folding the sheet to create a vertically extending free edge 15a as shown in FIGS. 1 and 2 and a vertically extending rounded or folded edge 15b. A sleeve 10 can be formed from the sheet 12. Thus, the free edge 15a and the ends 21, 22 can initially have a double layer or double thickness T of the sheets 12 on which the sheets overlap (see FIG. 2). The rounded edge 15b can have a slightly rounded curved shape or crease in cross section, including a single layer or a single thickness T of the sheet 12 (see also FIG. 2). ). In one embodiment, the sheet forming edge 15a and preferably the end 22 are then joined together (eg by heat fusion) to create a seam 16 fused along the edge 15a and the end 22. In one embodiment, the sleeve 12 thus formed defines an internal cavity 23 configured to receive the implant. Preferably, in one embodiment, the end 21 is not joined because an opening 18 for inserting the implant into the sleeve 10 is defined and created at the end 21. It should be noted that any suitable technique can be used to form the seal and close the free edge 15a and end 22 such as chemical fusion or welding, the use of biocompatible adhesives. I want to. Therefore, the present invention is not limited to the use of thermal fusion techniques.
In another embodiment, the sleeve can be formed by a method other than folding and splicing flat sheets of biocompatible material. In one embodiment shown in FIG. 10, the sleeve 100 can be formed in the form of a tube 112 having an opening or perforation 114 and two ends 116, 118. Preferably, in one embodiment, the tube 112 is seamless. In one possible embodiment, the tube 100 may be made of a polymer. In some possible embodiments, the polymer tube 112 can be formed by a pour-casting method or a dip-molding method. The pore casting method preferably comprises pouring the polymer solution into a tubular mold, coagulating the polymer and removing the formed tubular sleeve 112 from the mold. In one embodiment, a dip molding method is preferably formed by immersing a rod-shaped mandrel in a container of polymer solution, pulling up the mandrel to which the polymer clings from this solution, and coagulating the polymer. Includes removing the tubular sleeve 112 from the mandrel. The polymer solution used in this dip molding method preferably has a suitable viscosity that allows the polymer to adhere to the mandrel. One dip molding method that can be used in forming the sleeve 112 is disclosed in US Patent Application Publication No. 20050209629, which is incorporated herein by reference in its entirety. In some embodiments, the mandrel is soaked more than once to increase the thickness of the tubular sleeve 112. In another embodiment, the mandrel can be immersed in two or more containers of the same or different types of polymer solutions to create a multilayer tube 112. In some embodiments, two or more of the same or different polymer solutions comprises the same drug, different salts of the same drug, different drugs, or any combination thereof. Thus, multiple polymers that allow the type of drug administered, as well as the rate and duration of administration, to be adjusted according to the requirements of the particular application.
The opening or perforation 114 can be formed in the tube 112 by any suitable means. In one embodiment, the tube 112 can be flattened after the tube 112 has solidified if the selected tube material has sufficient elasticity. The perforation 114 is then formed by any suitable means, such as, but not limited to, using a press or other device to pierce / puncture this flattened tube. can do. In some embodiments, if the tube 112 is made of a non-elastic material that cannot be easily flattened, the perforation 114 is perforated by any suitable means of perforating the tube and forming a perforation. Can be formed. In another possible embodiment used with the cast tube 112, the mold comprises a plurality of columns or pins sized and configured to match the intended final shape and size of the perforations 114. obtain. When poured into the mold, the polymer solution flows around the column or pin. When the polymer solidifies, perforations 114 are formed at the same time that the tubular sleeve is made. The cast forming perforation 114 of the above method eliminates the additional manufacturing step of forming the perforation after the tube 112 has been made. The tube 112 can be made to have both open ends 116, 118, as shown in FIG. 10, or in some embodiments, either end 116 or 118. Can be formed as a closed end (not shown). The sleeve 10 made in the form of a seamless tube can generally have better strength than the sleeves of some embodiments that are folded and spliced together.
As shown in FIG. 2, one embodiment of the sleeve is the entire cross section in the transverse direction with respect to the length of the sleeve defined to extend in the direction of the edge 15a, prior to inserting the medical implant into the sleeve 10. Can have an oval or oval shape that is flattened. Thus, the upper surface 17t and lower surface 17b of the sleeve 10 can include a flat or flat portion as a whole, and in one possible embodiment, with a sleeve in which debris can be trapped in vivo. This whole flat or flat part is to eliminate unnecessary extra loose sleeve material (after the implant is inserted) that can form unwanted extremely large pockets between the implants. Approximately follows the shape of the complementary flat implant 30 shown. In another embodiment (not shown), the sheet 12 can be folded to create the sleeve 10 so that the shape of the tube can be substantially formed.
It is important to note that the polymer composition can be modified to produce a broader reabsorption profile. Alternative film manufacturing methods can also be used, especially if the drug of interest is pyrolyzed at the temperature used in the compression molding process. Alternatively, lower temperature film production methods can be used, such as, but not limited to, solvent casting, dip molding on a mandrel, and the like.
The sleeve 10 is preferably supplied separately in its own sterile pouch. The surgeon can use the sleeve 10 by removing the sleeve from the pouch and then sliding and stretching the sleeve over the implant 30. Implant 30 is completely slid into the sleeve 10 to the closed end 22 to achieve a relatively snug fit and eliminate unsupported excess slack sleeve material at its end. Alternatively, it can be slid close to the closed end 22. In addition, surgical scissors can be used to trim the sleeve 10 to remove excess sleeve length by cutting off the end 21 near the end of the implant 30. In some situations, it may be desirable to have a slightly tighter fit between the sleeve 10 and the implant 30 to eliminate overly lumpy material that could interfere with the attachment of the implant 30 to the surgical site. However, it should be noted that not all cases require a tight fit. To individually adapt the sleeve to the particular size and shape of the implant that needs to be included, the surgeon can modify the sleeve 10 using techniques similar to those described above. The implant encapsulated in the sleeve can then be inserted into the patient and fixed in place using standard methods. Advantageously, the surgeon can deliver the drug from a variety of implants through the sleeve, while the medical device provider delivers one or more drugs depending on the patient's condition or instructions to be treated. Freed from the burdensome logistics work of having and maintaining a large inventory of uncoated and coated implants, including.
Although the medical implant 30 is shown as a straight elongated plate, it should be understood that a number of different shapes and types of medical implants can be used with the present invention without limitation. Thus, with, but not limited to, non-bone plate devices such as non-orthopedic implants (eg, stents, pacemakers, dental implants, etc.) and other orthopedic implants (eg, tibial nails, thigh nails, spinal implants, etc.), sleeve 10 Can also be used. Thus, in some embodiments, the surgeon may combine two or more sleeves 10 of the same size and shape or of different sizes and shapes for implants with more complex shapes. For example, two or more sleeves for use with, but not limited to, bone plates or other types of medical implants with L-shape, T-shape, X-shape, H-shape, or implants of other types and shapes. You can combine 10. It should be recognized that in all cases the implant does not need to be completely encapsulated by the sleeve 10 to effectively deliver the drug or other bioactive substance to the surrounding tissue. Therefore, by using a combination of sleeves 10, various implant shapes can be adapted.
Reference to FIG. 5 shows an alternative embodiment of the sleeve 40 designed to release the drug from only one side of the implant to direct the drug to bone or nearby soft tissue, if desired. .. An embodiment of the sleeve 40 includes an open central portion 42 having only a single thickness of the seat 12 and pockets 44 formed at both end portions 46. This open configuration exposes one side of the implant 30 between pockets 44 and this configuration can be supplied to the surgeon in the form shown or the sleeve (shown in FIG. 1). By removing the central part of 10, the surgeon can create it in the operating room.
In another possible embodiment, prior to implantation, the sleeve 10 covers the autologous or allograft bone fragment to administer the drug and / or to use the sleeve as a transplant bone fragment containment device. Can be placed. For example, bone marrow aspirate (BMA) is often mixed with ChronOS granules (available from Synthes, Inc., West Chester, Pennsylvania, USA) or other forms of carriers. In one embodiment, the surgeon may fill the sleeve with the ChronOS-BMA mixture to prevent it from migrating from the implantation site. Some examples of other suitable carrier materials include Vitoss® (r) (available from Orthovita, Malvern, PA), Conduit® (r) (DePuy, Inc., USA). Includes calcium phosphate cancellous bone substitutes such as (available from Raynham, Massachusetts).
In one embodiment, the reabsorption time of the polymer sleeve and the associated drug dosing rate can be manipulated over days to years. The chemistry and type of polymer used provides a wide range of possible drug delivery kinetics and polymer reabsorption times. In addition, the reabsorption time and drug delivery rate can be manipulated by the thickness of the sheet used to build the polymer sleeve.
Other techniques can also be used to regulate the rate and duration of delivery of the drug or bioactive agent from the sleeve. For example, in one alternative embodiment shown in FIG. 3, the sleeve 50 can be formed from multiple polymer sheet layers having the same or different polymer compositions. The sleeve 50 can include two sheets 12 and 52, in one embodiment the two sheets 12 and 52 are integrally laminated by any conventional method known in the art. And may include perforations 50 as shown. In some embodiments, both sheets 12 and 52 do not need to contain perforations 14, respectively, if not desired. In one embodiment, the respective sheets 12, 52 may be impregnated with the drug, but the sleeve may be designed to release the drug at different rates. In one embodiment, this micropores one or several sheets 12, 52 to allow faster penetration of water or fluid into the film and faster elution of the drug. Can be achieved by The non-microporous layer captures the drug more effectively and elutes it at a slower rate. In another embodiment with sheets 12 and 52 made from different polymers, one sheet is more hydrophilic than the other and can swell at a faster rate by absorption of fluid, thereby. The drug can be released faster. Alternatively, one sheet 12 or 52 can be made from a polymer that decomposes faster in vivo than the other sheet. In some embodiments, the same drug or bioactive agent is incorporated into Sheets 12 and 52. In another embodiment, sheets 12 and 52 may include different drugs. Thus, for example, a first type of drug from Sheet 12 can be delivered at a given rate and duration, and a second different or same drug from Sheet 52 can be delivered at a given rate and duration. It can be delivered in a period.
In another embodiment, the drug or bioactive agent can be delivered at different rates and durations by incorporating different salts of one or more types of drugs into sleeves 10 or 50. In one embodiment, the sheet 12 of the sleeve 10 may contain different salts of the same drug, each with a different solubility in body fluids. Therefore, the rate of release of a drug varies according to the solubility of that particular salt. In one embodiment, this allows the dissolution profile of the drug from Sheet 12 to be adjusted by varying the ratio of different salts of the same drug present in the sheet. In another embodiment, the sheet 12 may contain different salts of two or more different drugs or bioactive substances. In an alternative embodiment of the sleeve 50 having a plurality of sheet layers 12, 52, the sheet 12 and the sheet 52 may contain different salts of the same drug.
See Figures 6-9, which do not have full flexibility or elasticity to allow stretching or stretching on the implant, but deformations such as holes and / or slits / slots cut in various directions on the sleeve. By providing a pattern of possible openings, alternative embodiments of sleeves 10 or 50 can be created from polymer sheets or films that can be stretched to fit many different size implants. These holes and / or slits / slots deform, allowing the sleeve to extend over the implant. FIG. 6 shows a possible embodiment of the polymer sheet 60 that includes a vertically extending slot 62. This arrangement allows the seat 60 to extend along the width of the seat 60 (running horizontally) in the direction of the indicated stretch arrow. FIG. 7 shows a possible embodiment of the polymer sheet 70 including a vertically extending slit 72. This arrangement allows the seat 70 to extend along the width of the seat 70 (running horizontally) in the direction of the indicated stretch arrow. FIG. 8 shows a possible embodiment of the polymer sheet 80 that includes a combination of vertical slits 82 and holes 84, in which the slits are arranged diagonally on the sheet. This arrangement allows the seat 80 to extend in the direction of the indicated stretch arrow along the width and length of the seat 80 (running horizontally). FIG. 9 shows a possible embodiment of the polymer sheet 90 including the X-shaped slit 92. This arrangement allows the seat 90 to extend in the direction of the indicated stretch arrow along the width of the seat 90 (running horizontally) and its length (running vertically). An alternative embodiment of the seat 90 provides an X-shaped slot instead of a slit.
As long as the polymer sheet can be stretched or stretched in one or more directions, it is possible to use a variety of other suitable shapes, combinations and patterns of deformable openings such as holes, slits, slots. I want to be understood. It should be recognized that these deformable openings can be used with flexible, semi-rigid or rigid polymer sheets for which very well stretchable sleeves are desired. These deformable openings can be used advantageously for the purpose of accommodating irregularly shaped implants whose contours are not perfectly linear.
The above description and accompanying drawings show preferred embodiments of the present invention, but various additions and modifications to those embodiments that do not deviate from the gist and scope of the present invention as defined in the appended claims. And understand that replacements can be performed. In particular, without departing from the spirit or essential features of the invention, the invention will be embodied in other particular forms, structures, arrangements, proportions and sizes, and will have other elements, materials and components. It is clear to those skilled in the art that it can be materialized. The present invention is used with many modifications of the structures, arrangements, proportions, sizes, materials and components used in the practice of the present invention, particularly adapted to specific needs and functional requirements, without departing from the principles of the present invention. Those skilled in the art should understand that they can. Therefore, the embodiments disclosed herein should be considered in all respects for purposes of illustration and not for limitation, and the scope of the invention is attached. It is defined by the scope of claims and is not limited to the above description or embodiment.
10 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US2002055749A1 | Cites | United States of America | Search report |
| US2002055749A1 | Cites | United States of America | Examiner |
| JP2003527193A | Cites | Japan | Search report |
| JP2003527193A | Cites | Japan | Examiner |
| JP2009511196A | Cites | Japan | Examiner |
| US5984926A | Cites | United States of America | Search report |
| US5984926A | Cites | United States of America | Examiner |
| JPH0744936B2 | Cites | Japan | Search report |
| JPH0744936B2 | Cites | Japan | Examiner |
| JPH08224297A | Cites | Japan | Search report |
| JPH08224297A | Cites | Japan | Examiner |
| JPH11216178A | Cites | Japan | Search report |
| JPH11216178A | Cites | Japan | Examiner |
37 members in 10 offices
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 60726808 | United States of America | – | |
| 72680805 | United States of America | P | |
| 72680805 | United States of America | P | |
| 2005726808 | – | – | – |
| US20050726808P | – | – | – |
Members37
| Document | Office | Kind | |
|---|---|---|---|
| AU2006304229A1 | Australia | A1 | |
| WO2007047420A2 | World Intellectual Property Organization (WIPO) | A2 | |
| CA2625264A1 | Canada | A1 | |
| WO2007047420A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO2007047420A8 | World Intellectual Property Organization (WIPO) | A8 | |
| EP1933936A2 | European Patent Office (EPO) | A2 | |
| KR20080068699A | Republic of Korea | A | |
| US2008262630A1 | United States of America | A1 | |
| JP2009511196A | Japan | A | |
| CN101437571A | China | A | |
| ZA200803822B | South Africa | B | |
| EP1933936A4 | European Patent Office (EPO) | A4 | |
| BRPI0617325A2 | Brazil | A2 | |
| JP2012250084AThis record | Japan | A | |
| CN101437571B | China | B | |
| JP5137841B2 | Japan | B2 | |
| KR20130048272A | Republic of Korea | A | |
| CN103251449A | China | A | |
| US2013289621A1 | United States of America | A1 | |
| KR101377900B1 | Republic of Korea | B1 | |
| KR101420988B1 | Republic of Korea | B1 | |
| JP2014147842A | Japan | A | |
| US8900620B2 | United States of America | B2 | |
| US2015018969A1 | United States of America | A1 | |
| JP5676541B2 | Japan | B2 | |
| CA2625264C | Canada | C | |
| CN103251449B | China | B | |
| JP5893672B2 | Japan | B2 | |
| US9579260B2 | United States of America | B2 | |
| US2017136223A1 | United States of America | A1 | |
| US2018085564A1 | United States of America | A1 | |
| EP1933936B1 | European Patent Office (EPO) | B1 | |
| EP3566742A1 | European Patent Office (EPO) | A1 | |
| BRPI0617325B1 | Brazil | B1 | |
| US10814112B2 | United States of America | B2 | |
| US2021031013A1 | United States of America | A1 | |
| BRPI0617325B8 | Brazil | B8 |
23 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Cancellation because of no payment of annual feesLAPS | LAPS | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Certificate of patent or registration of utility modelJAPANESE INTERMEDIATE CODE: R150R150 | R150 | |
| First payment of annual fees (during grant procedure)JAPANESE INTERMEDIATE CODE: A61A61 | A61 | |
| Written decision to grant a patent or to grant a registration (utility model)JAPANESE INTERMEDIATE CODE: A01A01 | A01 | |
| Decision of grant or rejection writtenTRDD | TRDD | |
| Request for written amendment filedJAPANESE INTERMEDIATE CODE: A523A521 | A521 | |
| Written permission of extension of timeJAPANESE INTERMEDIATE CODE: A602A602 | A602 | |
| Written request for extension of timeJAPANESE INTERMEDIATE CODE: A601A601 | A601 | |
| Written permission of extension of timeJAPANESE INTERMEDIATE CODE: A602A602 | A602 | |
| Written request for extension of timeJAPANESE INTERMEDIATE CODE: A601A601 | A601 | |
| Written permission of extension of timeJAPANESE INTERMEDIATE CODE: A602A602 | A602 | |
| Written request for extension of timeJAPANESE INTERMEDIATE CODE: A601A601 | A601 | |
| Notification of resignation of power of attorneyJAPANESE INTERMEDIATE CODE: A7424RD04 | RD04 | |
| Request for written amendment filedJAPANESE INTERMEDIATE CODE: A821A521 | A521 | |
| Notification of acceptance of power of attorneyJAPANESE INTERMEDIATE CODE: A7422RD02 | RD02 | |
| Written request for application examinationJAPANESE INTERMEDIATE CODE: A621A621 | A621 |
Numbers
- Publication
- 2012250084
- Publication, DOCDB
- 2012250084
- Publication, EPODOC
- JP2012250084
- Application
- 209414
- Application, DOCDB
- 2012209414
- Application, EPODOC
- JP20120209414
Titles2
- Japanese
- 薬物含浸容器
- English
- Drug impregnated container
Classification
- CPC, 33
- A61B17/8028
- A61N1/30
- A61M31/002
- A61F2/06
- A61F2/07
- A61F2002/072
- A61F2210/0004
- A61F2250/0067
- Y10T156/1051
- A61F2002/30919
- A61F2/44
- A61F2/02
- A61L31/148
- A61L31/16
- A61L31/06
- A61L31/146
- A61L2300/402
- A61L2300/404
- A61L2300/406
- A61L2300/416
- A61L2300/414
- A61B17/68
- A61B17/70
- A61B17/72
- A61J3/00
- A61M37/00
- A61J2200/00
- A61L27/54
- A61B2017/00004
- A61B2017/00893
- A61C8/0013
- A61F2/04
- A61M2205/04
- IPC, 4
- A61L27 00
- A61F2 02
- A61K6 00
- A61L31 00